
Chronic myeloid leukemia (CML) is a blood cancer caused by a specific genetic alteration known as the Philadelphia chromosome. This alteration leads to the fusion of two genes and the activation of abnormal signaling pathways. Treatment with tyrosine kinase inhibitors (TKIs) can effectively reduce the number of leukemia cells, but residual CML stem cells (CML-SCs) often remain, leading to potential relapse. CML-SCs share similar surface markers with normal hematopoietic stem cells (HSCs), making it difficult to distinguish between them. The study has identified specific surface markers associated with CML-SCs, but further analysis at the genetic level is necessary to understand the relationship between these markers, the presence of the fusion gene, and other genetic mutations in CML-SCs compared to normal HSCs.
Like
Save
Share